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Background: Peginterferon alpha-2a is a known standard ther-
apy for patients with acute HCV infection. Our experience with
peginterferon in hemodialised patients with hepatitis C started
with a million question and uncertainties. This because of the:
- acute phase of infection,which we encountered due to
repetitive serological tests the patients underwent because of
hemodialysis protocols.
- fragile,immunodepressed patients which had a lifetime with
serious underlying diseases,primary related to nephropathies or
not.
However efﬁcacy and safety of this treatment is still unclear
in regional settings. This study tends to evidence the efﬁcacy
and safety of peg-interferon therapy in Albanian hemodialysed
patients.
Methods & Materials: In a one-year period (from November
2013- November 2014), we enrolled consecutive patients with
detectable anti-HCV antibody andHCV-RNA in the serum,who had
elevated serum alanine aminotransferase (ALT). Written informed
consent was taken from them. Patients with decompensated cir-
rhosis were excluded and inwomen of fertility age,pregnancy tests
weredone24hoursprior to theﬁrst doseof peginterferonalpha-2a.
Underlyingdiseases in ourhemodialysedpatients includedChronic
renal failure -55 cases, Acute pyelonephritis - 1 case, Renal policys-
tosis – 6 cases,Congenital renal atrophy – 1 case, nephrolythiasis
-2 cases, renal transplant- 2 cases, nephroectomy- 3 cases, Arterial
hypertension- 2 cases, spondyloarthrosis – 1 case.
Results: Early virologic response and sustained virologic
response rates were 84.8% (47/55) 78.2% (42/55) respectively. The
most common adverse effects in descending order were ﬂue-like
symptoms (83%), hair loss 36.3%, anorexia 54.5%, weight loss 25.4%,
mood changes 40%, sleep disorders 29%, hematomas 41%, epistaxis
21.8% Laboratory data evidenced anemia 96.3%, leucopenia 78.1%,
thrombocytopenia 83.6%.
Conclusion: Our 55 patientsmanifested several adverse effects,
during therapy with peginterferon alpha-2a. Despite their par-
ticular immune status, these adverse affects appeared minimal
compared to the efﬁcacy of treatment in our patients
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Background: Recently, it has been showed that obesity strongly
increase risk of morbidity and mortality caused by cardiovascular
complications including atherosclerosis, cardiovascular disorders
(CD), coronary heart disease. Obesity which developes due to
multifactorial reasons, was associated with human Adenovirus-
36(Ad-36). In this study, we aimed to investigate the role of
adenovirus 36 induced obesity in CD.
Methods & Materials: In this cross-sectional and case-control
based study, 75 obese(BMI ≥ 30 kg/m2) adults with cardiovascular
problems, 28 non-obese(BMI ≤ 25 kg/m2) with cardiovascu-
lar problems, and also 48 people non-obese(BMI ≤ 25 kg/m2)
without cardiovascular problem were included in this study as
patient group(PG), patient control groups(PCG) andhealthy control
groups(HCG), respectively. For this purpose, mediastinal adipose
tissue samples obtained PG and PCG from anterior mediastinum
situated on the outer surface of pericardium during routine cardio-
vascular surgical procedures. Besides, the blood samples collected
from the each groups(PG, PCG and HCG). In this preliminary study,
the peresence of Ad-36 antibodies, leptin, adiponectin levels were
assessed by serum neutralization assay(SNA) and ELISA, respec-
tively. Mediastinal adipose tissue samples will be examined for the
presence of the Ad-36 DNA by PCR.
Results: Ad-36 antibody was detected in 10(13.3%) of 75
patients by SNA. We detected signiﬁcantly difference Ad-36 anti-
body levels in the PG compared to the PCG and HCG(p<0.05). Mean
BMI, leptin, LDL, triglyceride levels were higher in the PG, while
adiponectin, levels were found to be lower in the PG. Signiﬁcant
differenceswere detected between the PG and PCG for the parame-
tres(p <0.05), but there was no signiﬁcant differences for total
cholesterol .
Conclusion: In the light of our international literature review,
although we detected a signiﬁcant presence of Ad-36 antibodies
related with obesity in adults with CD for the ﬁrst time in this pre-
